Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening can

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening can

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections - fluconazole-baxter intravenous infusion should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. vaginal candidiasis, when topical therapy has failed. 6. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening can

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - glucose as monohydrate - solution for infusion - glucose as monohydrate 500 g / 1 l - glucose - high caloric carbohydrate infusion, hypoglycaemia

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - carboplatin -

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 400 mg/l; sodium lactate, quantity: 3.22 g/l; calcium chloride dihydrate, quantity: 270 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; lactic acid; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions. this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 6 g/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 2.2 g/l; calcium chloride dihydrate, quantity: 270 mg/l - injection, solution - excipient ingredients: lactic acid; sodium hydroxide; water for injections - this product accepted for registration/listing as 'currently supplied' at the time of commencement of the act. indications held in artg paper records. (old code)

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - calcium chloride dihydrate, quantity: 270 mg/l; sodium lactate, quantity: 3.22 g/l; potassium chloride, quantity: 400 mg/l; sodium chloride, quantity: 6 g/l - injection, solution - excipient ingredients: sodium hydroxide; water for injections - is indicated as a source of water and electrolytes. it is also used in patients as a source of bicarbonate in the treatment of mild to moderate metabolic acidosis associated with dehydration or associated with potassium deficiency. these solutions are indicated as methods of intravenous drug delivery, if the drugs are comparable with the solutions.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - indications ,bupivacaine-claris is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.